Q4 2024 Lineage Cell Therapeutics Inc Earnings Call Transcript
Key Points
- Lineage Cell Therapeutics Inc (LCTX) reported that their lead candidate, OpRegen, is progressing well in the Phase 2a GAlette study, with no impact from Roche's recent pipeline reductions.
- The company has secured RMAT designation for OpRegen, indicating a positive regulatory outlook.
- Lineage's manufacturing capabilities are highlighted as a competitive advantage, with scalable GMP production processes in place.
- The company has extended its cash runway into Q1 2027, supported by a recent financing strategy that includes milestone warrants.
- Lineage's OPC1 program for spinal cord injury is advancing with a new delivery device and improved manufacturing process, potentially expanding its clinical applications.
- Lineage Cell Therapeutics Inc (LCTX) has not received interim data from Roche's ongoing Phase 2a trial, creating uncertainty about the timing of future updates.
- The company's revenue increase is primarily driven by deferred collaboration revenue, indicating potential reliance on partnerships for financial growth.
- Operating expenses remain high, with a total of $31 million for the year, despite a decrease from the previous year.
- The net loss for the year was $18.6 million, reflecting ongoing financial challenges.
- There is significant competition in the RPE transplant space, with multiple companies reporting positive data, which could impact Lineage's market position.
Thank you for standing by. My name is Rochelle, and I will be your conference operator today. At this time, I would like to welcome everyone to the Lineage Cell Therapeutics fourth-quarter and full-year 2024 conference call.
(Operator Instructions)
An audio webcast of this call is available on the investor section of Lineage's website at www.LineageCell.com. This call is subject to copyright and is the property of Lineage, and recordings, reproductions, or transmissions of this call without the express written consent of Lineage are strictly
prohibited. As a reminder, today's call is being recorded.
I would now like to introduce your host for today's call, Ioana Hone, Head of Investor Relations at Lineage.
Ms. Hone, please go ahead.
Thank you, Rochelle. Good afternoon, and thank you for joining us. A press release reporting our fourth-quarter and full-year 2024 financial
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
